An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin treated patients with coronary heart disease and persisting hypertriglyceridaemia

Heart

Volumn 85, Issue 5, 2001, Pages 544-548

  Durrington, P N ^a   Bhatnagar, D ^a   Mackness, M I ^a   Morgan, J ^a   Julier, K ^a   Khan, M A ^a   France, M ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Coronary heart disease; Hypertriglyceridaemia; Polyunsaturated fat; Statin treatment

Indexed keywords

OMEGA 3 FATTY ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034762548     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/heart.85.5.544     Document Type: Article

References (26)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease; the Scandinavian survival study
2. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
3. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
4. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia
5. Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia
6. Effects of simvastatin and omega-3 fatty acids on plasma lipoprotein and lipid peroxidation in patients with combined hyperlipidaemia
7. Joint effects of HMG-CoA reductase inhibitors and eicosapentanoic acids on serum lipid profile and fatty acid concentrations in patients with hyperlipidaemia
8. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: Diet and reinfarction trial (DART)
9. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: Final report of the Lyon diet heart study
10. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione trial
11. Effect of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia
12. Fish oils and plasma lipid and lipoprotein metabolism in humans: A critical review
13. Fish consumption, fish oil, lipids and coronary heart disease
14. Elevated plasma glucose and lowered triglyceride levels from omega-3 fatty acid supplementation in type II diabetes
15. Adverse metabolic effect of omega-3 fatty acids in non-insulin-dependent diabetes mellitus
16. Dietary marine fish oils and insulin action in type 2 diabetes
17. The hypotriglyceridaemic effect of fish oil in adult-onset diabetes without adverse glucose control
18. Effect of glyburide and omega 3 fatty acid dietary supplements on glucose and lipid metabolism in patients with non-insulin-dependent diabetes mellitus
19. Effects of low-dose EPAE on glycemic control, lipid profile, lipoprotein (a), platelet aggregation, viscosity and platelet and vessel wall interaction in NIDDM
20. N-3 fatty acids do not lead to an increased diabetic risk in patients with hyperlipidaemia and abnormal glucose tolerance. Italian fish oil multicenter-study
21. Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM: A randomised, prospective, double-blind, controlled study
22. Fish oil and glycemic control in diabetes. A meta-analysis
23. Serum triglycerides and HDL cholesterol-major predictors for long-term survival after coronary surgery
24. Lipid-lowering drugs: Who gets what?
25. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
26. Comparisons of statins in hypertriglyceridaemia